tbuckley/cabot-search huggingface dataset:
Medical Economics
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FOURIER PHASE ANALYSIS IN NON-CYCLIC DYNAMIC STUDIES
Authors: Michael F. Hartshorne, Robert J. Telepak, Stephen R. Bunker, Jack L. Lancaster, Craig S. Hammes, Ralph Blumhardt
Journal: Clinical Nuclear Medicine (1982)

Hartshorne, Michael F.; Telepak, Robert J.; Bunker, Stephen R.; Lancaster, Jack L.; Hammes, Craig S.; Blumhardt, RalphAuthor Information
Hypertensive crisis
Authors: F. A. Finnerty
Journal: JAMA (1974)

HYPERTENSIVE encephalopathy is a syndrome consisting of a sudden elevation of arterial blood pressure usually preceded by severe headache and followed by convulsions, coma, or a variety of transitory cerebral phenomena. The syndrome may complicate any type of hypertension, acute glomerulonephritis, toxemia of pregnancy, or essential or malignant hypertension. From the hemodynamic standpoint, encephalopathy is associated with an increase in arterial blood pressure, diminished cerebral blood flow, and cerebral arteriolar constriction. The constancy of increased blood pressure and the frequency of a sharp rise in arterial blood pressure preceding the attack, suggests that the hypertension (or the phenomena that are concerned in its production) are causally related to the cerebral syndrome. The sudden waxing and waning, the variability and the transitory nature of the cerebral phenomena seen in all types of hypertensive encephalopathy suggest a rapid decrease in cerebral blood flow caused by a sudden increase in cerebral vasoconstriction. The
Overexpression of S100A9 in obesity impairs macrophage differentiation via TLR4-NFkB-signaling worsening inflammation and wound healing
Authors: Sandra Franz, Anastasia Ertel, Kathrin M Engel, Jan C. Simon, Anja Saalbach
Journal: Theranostics (2022)

Rationale:In obesity the fine-tuned balance of macrophage phenotypes is disturbed towards a dominance of pro-inflammatory macrophages resulting in exacerbation and persistence of inflammation and impaired tissue repair.However, the underlying mechanisms are still poorly understood.Methods: Impact of obesity on macrophage differentiation was studied in high fat diet induced obese and db/db mice during skin inflammation and wound repair, respectively.Mechanisms of S100A9-mediated effects on macrophage differentiation was studied on in vitro generated macrophages by genomic and proteomic approaches.The role of S100A9 on macrophage differentiation was investigated by pharmacological inhibition of S100A9 during skin inflammation and wound repair in obese and db/db mice. Results:We demonstrate an overexpression of S100A9 in conditions of obesity-associated disturbed macrophage differentiation in the skin.We show that saturated free fatty acids (SFA), which are increased in obesity, together with S100A9 induce TLR4 and inflammasome-dependent IL-1β release in macrophages which in turn amplifies S100A9 expression initiating a vicious cycle of sustained S100A9 overexpression in skin inflammation in obesity.We reveal a yet unrecognized impact of obesity-associated S100A9 overexpression on macrophage differentiation.S100A9 binding to TLR4 and activation of NFkB attenuates development of M2-like macrophages and induces pro-inflammatory functions in these cells.Consequently, inhibition of S100A9 restores disturbed M2-like macrophage differentiation in mouse models of obesity-associated skin inflammation and wound repair.Similarly, breaking the vicious cycle of S100A9 overexpression by dietary reduction of SFA restored M2-like macrophage activation.Improvement of skin inflammation and wound repair upon reduction of S100A9 by pharmacological inhibition or by reduction of SFA uncovers the pathogenic role of S100A9 overexpression in obesity. Conclusion:This study identifies S100A9 as a previously unrecognized vital component in obesity-associated disturbed macrophage differentiation and subsequent impaired regulation of inflammation and wound repair.The findings open new opportunities for therapeutic implications for inflammatory diseases and wound repair in obesity.
What we owe to our patients
Authors: M. Grossman
Journal: JAMA (1982)

With his report on confidentiality (p 2695), Weiss has performed a worthy service, if readers note but one finding: patients have faith in our professed principles of ethics. Their faith, however, may be greater than our practice warrants. Some of the difference in the responses of the patients, house staff, and students may be due to the semantics of the questionnaire. The use of<i>interesting</i>instead of<i>instructional</i>beclouds the issue and findings. The essence of the case cited by the author,<i>Doe v Roe</i>,<sup>1</sup>is that it is not only legitimate but essential that clinical material be published for the educational needs of the medical profession. However, endangering the patient's privacy is not warranted merely because the material might be interesting. This is in keeping with our medical ethics. We must recognize the legal position that the innate, constitutionally supported right to privacy belongs to the patient. In
The abandoned children of the Islamic State
Authors: None The Lancet Child & Adolescent Health
Journal: The Lancet Child & Adolescent Health (2020)

Since April, 2016, thousands of Iraqi and Syrian civilians, displaced by a decade of war, have been living in refugee camps in northeastern Syria. In the largest camp, Al Hol, 90% of the 65 000 residents are women and children, two thirds are minors, and the vast majority are younger than 8 years old. A separate annex guarded by the Kurdish Syrian Democratic Forces houses 10 000 residents, the families of third-country nationals with links to the Islamic State.
SOCIETY NEWS.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Teaching the behavioural sciences.
Journal: BMJ (1967)

Hazards of Therapy: Carcinogenic action of new therapeutic agents cannot be predicted from their chemical structure, and co-operation between laboratory workers and clinicians is of paramount importance in avoiding this potential danger (p.129).Acrylamide Poisoning: Six cases in Britain.Clinically characterized by peripheral neuro- pathy and a midbrain disturbance.Prevention is relatively easy (p.134).Leader at p. 125.Fructose Intolerance: Genetically determined metabol c disorder which may present in infancy, childhood, or adult life.It is prevented by ex- cluding fructose from the diet (p.138).Pulmonary Valve Closure: Delay, causing split- ting of second heart sound, observed in eight patients with renal failure.Splitting disappeared after correction of oedema.It seems a useful sign of fluid overload (p.141).Role of Glucagon: Blood glucose levels affected more by its glycogenolytic action than by its insulin release action (p.145).Coronary Occlusion and the Thyroid: Blood fibrinolytic enzyme system is probably influenced by thyroid hormones (p.147).Fat Embolism: Lipaemia found in series of
Les aliénés et les correctionnaires à Saint-Lazare au XVIIe et au XVIIIe siècles.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hypertensive end organ damage and premature mortality are p38 MAPK dependent in a rat model of cardiac hypertrophy and failure Thomas M. Behr, Sandhya S. Nerurkar, Allen H. Nelson, Tina Woods, Anthony Sulpizio, Sudeep Chandra, David Brooks, John C. Lee, Robert W. Coatney, Christiane E. Angermann, Jonathan D. Sackner-Bernstein, Joseph Sisko, Jerry Adams, Eliot H. Ohlstein, Robert N. Willette. SmithKline Beecham, King of Prussia, PA
Journal: Journal of the American College of Cardiology (2001)
The British Society of Gastroenterology
Authors: M Bateson, D Trash, K Sloper, D Smith, G Brook, D Kingston, J Pearson, M Shiner, W Ruddell, J Findlay, A Axon, A Bartholomew, M Hill
Journal: Gut (1980)

A joint meeting of the Association of Surgeons, the British Society ot Gastroenterology, and the British Society for Digestive Endoscopy took place in Bournemouth on Wednesday, 26 to Saturday, 29 March.The very full and varied scientific programme was preceded and followed by Symposia, teaching days, and satellite sessions and supported by a varied social programme.Abstracts of scientific communications read before the Societies follow.CLINICAL I usual with CDCA but rare with UDCA.We concluded that outcome of dissolution therapy may be predicted from a six month cholecystogram; UDCA is no more efficacious than CDCA.Can a six-month cholecystogram predict eventual response to gallstone dissolution therapy?
Grant Numbers Added to Funding/Support
Journal: JAMA Network Open (2020)

Bingyao Tan, PhD; Jacqueline Chua, PhD; Emily Lin, BSc; Joyce Cheng, BSc; Alfred Gan, MSc; Xinwen Yao, PhD; Damon W. K. Wong, PhD; Charumathi Sabanayagam, PhD; Doric Wong, MD; Choi Mun Chan, MD; Tien Yin Wong, MD, PhD; Leopold Schmetterer, MD, PhD; Gavin S. Tan, FRCSEd, PhD
Assessing the relationship between obesity and long-term clinical and economic outcomes in coronary artery disease patients Eric L. Eisenstein, Linda K. Shaw, Charlotte L. Nelson, Kevin J. Anstrom, Zafar Hakim, Daniel B. Mark, Duke University Medical Center, Durham, NC, Roche Global Pharmacoeconomics Research, Palo Alto, CA
Journal: Journal of the American College of Cardiology (2001)
COVID-19: global consequences for oncology
Authors: None The Lancet Oncology
Journal: The Lancet Oncology (2020)

As the coronavirus disease 2019 (COVID-19) pandemic escalates and countries struggle to contain the virus, health-care systems are under increasing pressure. Emergency departments and intensive care units are nearing breaking point, and medical resources are being diverted to tackle the crisis. Moreover, conferences are being cancelled, and research trials are grinding to a halt. So what does COVID-19 mean for patients with cancer, their physicians, and the wider oncology discipline?
Post procedure chest pain after coronary stenting represents myonecrosis: Implications on clinical restenosis Samin K. Sharma, Paul Lee, Mary E. Duffy, Paul Andrews, Cristina A. Mitre, Varinder Singh, Nohella Perez, Mazzulah Kamran, David Reich, Annapoorna S. Kini. The Mount Sinai Medical Center, New York, NY
Journal: Journal of the American College of Cardiology (2001)
TCTAP A-047 Long Term Outcome of Unprotected Left Main Coronary Artery Disease: Comparison between Coronary Artery Bypass Grafting(CABG) and Percutaneous Coronary Intervention(PCI) in Korean Single Center
Authors: Kai Song, Moo Hyun Kim, Jia Xin Li
Journal: Journal of the American College of Cardiology (2018)
Errors in Figure 2
Journal: JAMA Neurology (2021)

Susan P. Mollan, MBcHB; James L. Mitchell, MBcHB; Ryan S. Ottridge, MPhil; Magda Aguiar, PhD; Andreas Yiangou, MBBS; Zerin Alimajstorovic, PhD; David M. Cartwright, MRes; Olivia Grech, MRes; Gareth G. Lavery, PhD; Connar S. J. Westgate, PhD; Vivek Vijay, MBBS; William Scotton, MBBS; Ben R. Wakerley, PhD; Tim D. Matthews, MBcHB; Alec Ansons, MBcHB; Simon J. Hickman, PhD; James Benzimra, BM, BCh; Caroline Rick, PhD; Rishi Singhal, MD; Abd A. Tahrani, PhD; Kristian Brock, PhD; Emma Frew, PhD; Alexandra J. Sinclair, PhD
Abstract 17032: Substrate Stiffness Alters the Kinetics of Sodium Channel Nav1.5 and Depolarization of Cardiomyocytes
Authors: Yutao T Xi, Sheng-An T Su, Luiz C Sampaio, Shui Ping T So, Junping T Sun, Jie T Cheng, Meixiang Xiang, Doris A Taylor
Journal: Circulation (2018)

Background: Myocardial scarring after infarction (MI) can create areas of slowed conduction, which can lead to re-excitation of the heart, or re-entry. Reentrant arrhythmia is one of the electrophysiological mechanisms responsible for ventricular tachycardia after acute myocardial infarction (AMI). Since the sodium channel (Na v 1.5) is a major contributor to cardiac electrical conduction, the objective of this study was to evaluate the effect of cell substrate stiffness on the kinetics of the Na v 1.5. Methods: MI was created by permanent ligation of the left anterior descending artery in rats. After 7 days, hearts were decellularized and grossed into 1 mm rings for measuring stiffness by using an atomic force microscope. The hearts had an elastic modulus of 263.33±76.8 kPa at scar, and 27.26±3.97 kPa at a remote area (n=3). The surface of p olydimethylsiloxane (PDMS) gels was tuned to match the stiffness of decellularized infarcted rat hearts (17.04±2.02 kPa, 110.56±8.70 kPa and 328.4±45.72 kPa, respectively, n=3). Human embryonic kidney 293 (HEK-293) cells were induced to stably express human Na v 1.5. HEK-293 and human pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were separately cultured on the PDMS substrate that mimicked stiffness of infarcted rat hearts for 24 h. Sodium channel currents (I Na ) and action potentials (APs) were recorded by patch clamp techniques. Results: As substrate stiffness increased, HEK-293 voltage dependent activation of Na v 1.5 (I Na ) shifted significantly towards more positive voltage (Vhalf: -28.42±5.12 mV, -33.47±6.98 mV, -19.84±5.24 mV, respectively, p&lt;0.01 in one-way ANOVA, n=12), and the transition from closed-state into inactivation was faster (tau: 48.47±4.60ms, 40.67±8.07ms, 81.20±9.54ms, p&lt;0.05, n=12). However, the current density, the steady-state inactivation curve and the recovery time were comparable between different PDMS. In iPSC-CMs, the slope of AP upstroke was decreased when stiffness was increased (30.00±1.38V/s, 23.91±0.65V/s, 20.93±0.34V/s, p&lt;0.05, n=15). Conclusion: Increased substrate stiffness, similar to myocardial scar, alters the kinetics of Na v 1.5 and affects the depolarization of cardiomyocytes, which likely contributes to slow conduction after MI.
TCT-513 The Impella Micro-axial Flow Catheter is Safe and Effective for Treatment of Myocarditis Complicated by Cardiogenic Shock: An Analysis from the Global cVAD Registry
Authors: Shiva Annamalai, Michele Esposito, Sudeep Kuchibhotla, Shelley Hall, Theodore Schreiber, William O'Neill, Navin Kapur
Journal: Journal of the American College of Cardiology (2017)
Genomic predictors of benefit from checkpoint inhibition in neuroendocrine carcinoma.
Authors: Patrick Walsh McGarrah, Jennifer Gile, Alex John Liu, Aaron Scott Mansfield, Konstantinos Leventakos, Aakash Desai, Sri Harsha Tella, Bassam Bassam Sonbol, Jason S. Starr, Timothy J. Hobday, Thorvardur Ragnar Halfdanarson
Journal: Journal of Clinical Oncology (2022)

512 Background: The role of immune checkpoint inhibitors (ICIs) in the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC) has yet to be established. While objective responses have been observed, it is still unknown which patients are likely to derive benefit. We investigated the genomic profiles of patients who did and did not benefit from ICIs. Methods: Previously we reported the objective responses to ICI in a retrospective series of patients with EP-NEC. RECIST 1.1 criteria were used to categorize patients as achieving disease control (DC = CR, PR, or SD) vs progressive disease (PD). The EMR was reviewed to identify patients who had genomic panels performed, and results were extracted for analysis. Results: Of 31 patients eligible for RECIST assessment, 19 had genomic panels available (9 with DC: 4 SD, 5 PR vs 10 with PD). Of those with NEC histology specified, 9 were small cell, 1 combined large and small cell, 3 were large cell. All tumors were microsatellite-stable. All but one (with TMB = 25) of 16 tumors with TMB status available were &lt; 10 m/MB. Of those with disease control, 67% had both TP53 and RB1 alterations, compared with only 10% in those with progressive disease; this was statistically significant ( p = 0.0198, Fisher exact). Of 7 tumors with TP53 + RB1 alterations, 4 were specified as small cell carcinoma. Half of those with PD showed alterations in β-catenin pathway genes CTNNB1 or APC, compared to only one of the DC group, but this did not reach significance ( p = 0.1409, Fisher exact). In an analysis of all Mayo patients (not just those treated with ICI) with NGS data available (Tempus and FoundationOne), concurrent TP53 + RB1 alteration was significantly more common in SCLC than in EP-NEC (Table). Conclusions: In this small series of patients with EP-NEC treated with ICIs, the SCLC-like genomic signature of concurrent TP53 + RB1 alterations was significantly more common in those with disease control than in those with progressive disease. An analysis of all patients with NGS data (not just on ICI) showed that the dual alteration was more common in SCLC, and SCLC also had more TMB-high tumors. This may explain why ICIs are more effective in SCLC than in EP-NEC. Further study is warranted to determine whether TP53 + RB1 mutations predict response to ICI in NEC.[Table: see text]
An intelligent on-line multicenter database created for the greater New York heart failure consortium registry on heart failure with preserved left ventricular systolic function Foss Tighe, Marc Klapholz, Julia Nisbet-Brown, Stuart Katz, Patti Nash, Matthew Maurer, Jay Meisner, Marrick Kukin, Judith Mitchell, David Baran, Rachel Bijou, Jill Kalman, Richard Steingart, Robert Phillips, Thierry LeJemtel. New England Research Institutes, Watertown, MA, Saint Vincents Hospital and Medical Center, …
Journal: Journal of the American College of Cardiology (2001)
Pancreatic cancer detection using 5-hydroxymethylation signatures in plasma-derived cell free DNA in high-risk patients with new onset diabetes.
Authors: David Haan, Gulfem Guler, Anna Bergamaschi, Wayne Volkmuth, Samuel Levy
Journal: Journal of Clinical Oncology (2022)

539 Background: Pancreatic cancer (PaCa) is the third leading cause of cancer death in the United States despite a low incidence rate. It is often diagnosed when cancer has already metastasized to distant organs. Late diagnosis deprives patients of potentially curative treatments such as surgery and impacts survival rates. People with new onset diabetes (NOD) are at 6-8 fold increased risk for PaCa compared to the general population. Indeed, 0.85% of patients with NOD will be diagnosed with PaCa within 3 years. This population of PaCa patients with NOD constitute 25% of all new pancreatic cancer diagnoses. Surveillance of the NOD population for PaCa presents an opportunity to shift PaCa diagnosis to earlier stage. Methods: Whole blood was obtained from a cohort of 167 PaCa patients and 490 patients with cancers other than PaCa as well as 836 non-cancer controls with and without NOD. Plasma was processed to isolate cfDNA and 5hmC libraries were generated and sequenced. 5hmC data is used to generate models for PaCa detection using Bluestar Genomics’s technology platform. Results: To investigate whether PaCa can be detected in plasma, we interrogated plasma-derived cfDNA hydroxymethylation in PaCa patients and non-cancer controls. Models trained using 5hmC-based biomarkers from cfDNA consistently performed with a mean test sensitivity of 61.1% [95% confidence interval (CI): 35.7% to 82.7%] and a test specificity of 97.6% (CI: 93% to 99.5%) measured across 50 cross validation iterations within the training data set, which was composed of 48.3% early stage (Stages I &amp; II) disease. The final model was trained using all of the training data, yielding 58.4% (CI: 47.5% to 68.8%) sensitivity at 98% (CI: 96.5% to 99.0%) specificity. This model was then tested on an independent test set with 22 PaCa patients (51.7% early stage, 15 of which was NOD) and 123 non-cancer control patients (53 of which were NOD) and yielded a classification performance of 59.1% (CI: 36.4% to 79.3%) sensitivity at 95.9% (CI: 90.8% to 98.7%) specificity. The model performance in the subset of patient cohort with NOD was 53.3% (CI: 26.6% to 78.7%) sensitivity at 94.3% (CI: 84.3% to 98.8%) specificity. Lastly, sensitivity observed on an independent validation set, composed of 56 PaCa and 117 ITTP samples, was 46.4% (CI: 33.0% to 60.2%) with 100% (CI: 96.8 to 100%) specificity. Conclusions: Our results demonstrate PaCa detection in plasma-derived cfDNA using 5hmC profiles. Overall, the model performed consistently between the training and independent validation datasets. A larger clinical study is under development to clinically validate the model described in this study with the goal of identifying occult PaCa within the NOD population in order to enable earlier detection and thus improve patient outcomes.